Mike Andrea, Kincses Zsigmond Tamás, Vécsei László
Petz Aladár Megyei Oktató Kórház, Neurológiai Osztály, Gyõr.
Szegedi Tudományegyetem, Neurológiai Klinika, Szeged.
Ideggyogy Sz. 2017 Jan 30;70(1-2):15-24. doi: 10.18071/isz.70.0015.
Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early course of the disease, however have substantial significance from the viewpoint of the long-term disease prognosis. MRI has an increasingly important role in the early monitoring of the therapeutic efficacy. In the last 15 years several clinical trials have been conducted with alemtuzumab and teriflunomide in multiple sclerosis providing evidence about the favourable clinical effect of these drugs. MRI images were acquired in these trials as well, and the results published recently in the scientific literature. These MRI results denote the suppression of the disease activity and the neurodegenerative processes, which may imply a favourable effect on the long-term prognosis of the disease.
我们的研究旨在回顾在复发性硬化症患者接受阿仑单抗和特立氟胺治疗过程中所获得的磁共振成像（MRI）已发表结果。在复发性硬化症中，MRI能够灵敏地检测到亚临床病理过程，这些过程在疾病早期不会表现出临床症状，但从疾病长期预后的角度来看具有重要意义。MRI在早期监测治疗效果方面发挥着越来越重要的作用。在过去15年里，针对复发性硬化症患者开展了多项使用阿仑单抗和特立氟胺的临床试验，为这些药物的良好临床效果提供了证据。这些试验中也采集了MRI图像，相关结果最近发表在了科学文献中。这些MRI结果表明疾病活动和神经退行性过程受到了抑制，这可能预示着对疾病的长期预后有积极影响。
